Resources from the U.S. Food and Drug Administration (FDA)

Resources from the Mayo Clinic

Publications
  Title Journal Description
Nature SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

This pre-clinical study showed that an mRNA vaccine against COVID-19 induced potent neutralizing antibody responses and CD8 T cell responses and protected against SARS-CoV-2 infection in the lungs and nose of mice without evidence of vaccine-associated enhanced respiratory disease (VAERD) when given at sub-protective doses.

New England Journal of Medicine Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

This pre-clinical study showed a two-dose vaccination schedule of mRNA-1273 led to a robust immune response and protection against SARS-CoV-2 infection in the upper and lower airways in non-human primates, without evidence of vaccine-associated enhanced respiratory disease (VAERD).

New England Journal of Medicine An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

This Phase 1 interim analysis showed that an mRNA vaccine against COVID-19 induced rapid and strong immune responses against SARS-CoV-2, supporting further clinical development and the potential of mRNA as a vaccine platform.

New England Journal of Medicine Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Phase 1 clinical study of mRNA-1273 vaccine against SARS-Cov-2 showed a higher level of neutralizing antibodies with a 100-µg dose in healthy older adults with an acceptable safety profile.